Investor Aisling Capital Iii Lp
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Aisling Capital Iii Lp . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2019-02-15 13D/A LOXO / Loxo Oncology, Inc. 2,038,920 0
2019-01-15 13D/A LOXO / Loxo Oncology, Inc. 2,038,920 2,038,920
2018-07-12 13D/A LOXO / Loxo Oncology, Inc. 3,688,920 2,038,920
2018-06-05 13D/A ASXC / Asensus Surgical, Inc. 11,490,831 6,389,352
2018-02-07 13G/A 0HBB / Aimmune Therapeutics Inc 2,990,000 2,240,000
2018-02-07 13G/A TTOO / T2 Biosystems, Inc. 2,830,992 0
2018-02-07 13G/A ARAV / Aravive, Inc. 2,524,465 0
2018-02-01 13D/A AGRX / Agile Therapeutics, Inc. 1,855,905 1,855,905
2018-02-01 13D/A PTX / Pernix Therapeutics Holdings, Inc. 2,218,008 221,809
2017-11-28 13D/A LOXO / Loxo Oncology, Inc. 4,188,920 3,688,920
2017-11-21 13D/A ASXC / Asensus Surgical, Inc. 11,490,831 11,490,831
2017-11-20 13D/A ASXC / Asensus Surgical, Inc. 10,335,819 11,490,831
2017-05-09 13D/A ASXC / Asensus Surgical, Inc. 8,335,819 10,335,819
2017-02-03 13G/A ARAV / Aravive, Inc. 2,279,568 2,524,465
2017-02-03 13G/A CYNA / Cynapsus Therapeutics Inc. 1,021,381 0
2017-02-03 13G/A TTOO / T2 Biosystems, Inc. 2,830,992 2,830,992
2017-01-12 13D/A LOXO / Loxo Oncology, Inc. 4,028,920 4,188,920
2016-10-27 13D/A AGRX / Agile Therapeutics, Inc. 2,277,334 1,855,905
2016-10-03 13D/A AGRX / Agile Therapeutics, Inc. 2,585,676 2,277,334
2016-06-03 13D/A AGRX / Agile Therapeutics, Inc. 2,585,676
2016-05-27 13D LOXO / Loxo Oncology, Inc. 3,796,362 4,028,920
2016-02-05 13G/A ARAV / Aravive, Inc. 2,279,568
2016-02-05 13D/A ASXC / Asensus Surgical, Inc. 8,335,819
2016-02-05 13G/A SRNE / Sorrento Therapeutics, Inc. 3,855
2016-02-05 13G 0HBB / Aimmune Therapeutics Inc 2,990,000
2016-02-05 13G/A EVAR / Lombard Medical, Inc. 886,363
2016-02-05 13G/A LOXO / Loxo Oncology, Inc. 3,796,362
2016-02-05 13G/A CYNA / Cynapsus Therapeutics Inc. 921,381 1,021,381
2016-02-05 13G/A TTOO / T2 Biosystems, Inc. 2,830,992
2015-11-20 13D/A ZLTQ / ZELTIQ Aesthetics, Inc. 2,360,672
2015-07-14 13G/A ROKA / Roka Bioscience, Inc. 876,368
2015-06-30 13G CYNA / Cynapsus Therapeutics Inc. 921,381
2015-04-27 13D/A PTX / Pernix Therapeutics Holdings, Inc. 2,218,008
2015-02-02 13G ROKA / Roka Bioscience, Inc. 1,122,417
2015-02-02 13G TTOO / T2 Biosystems, Inc. 2,523,300
2015-02-02 13G LOXO / Loxo Oncology, Inc. 3,452,493
2015-01-29 13G ARAV / Aravive, Inc. 2,139,568
2015-01-27 13D/A AGRX / Agile Therapeutics, Inc. 2,983,797
2014-11-19 13D/A DRTX / Durata Therapeutics Inc 0
2014-07-01 13G EVAR / Lombard Medical, Inc. 886,363
2014-05-30 13D AGRX / Agile Therapeutics, Inc. 2,171,831
2014-05-28 13D/A DRTX / Durata Therapeutics Inc 2,283,695
2014-05-23 13G SRNE / Sorrento Therapeutics, Inc. 1,763,500
2014-04-23 13D/A ASXC / Asensus Surgical, Inc. 8,335,819
2014-03-24 13D/A DRTX / Durata Therapeutics Inc 3,030,175
2014-01-27 13D/A ZLTQ / ZELTIQ Aesthetics, Inc. 2,602,439
2013-12-10 13D/A ASXC / Asensus Surgical, Inc. 36,490,260
2013-11-15 13D/A ZLTQ / ZELTIQ Aesthetics, Inc. 3,597,742
2013-09-13 13D ASXC / Asensus Surgical, Inc. 36,490,260
2012-07-26 13D DRTX / Durata Therapeutics Inc 3,130,824